| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:CXL-1020
CAS:950834-06-7
Package:25mg/RMB 10600;100mg/RMB 17500;50mg/RMB 13800
|
CXL-1020 manufacturers
- CXL-1020
-
- $1520.00 / 25mg
-
2025-10-27
- CAS:950834-06-7
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | CXL-1020 Basic information |
| Product Name: | CXL-1020 | | Synonyms: | CXL-1020;N-hydroxy-2-methylsulfonylbenzenesulfonamide;Benzenesulfonamide, N-hydroxy-2-(methylsulfonyl)- | | CAS: | 950834-06-7 | | MF: | C7H9NO5S2 | | MW: | 251.28 | | EINECS: | | | Product Categories: | | | Mol File: | 950834-06-7.mol |  |
| | CXL-1020 Chemical Properties |
| form | Solid | | color | White to off-white |
| | CXL-1020 Usage And Synthesis |
| Uses | CXL-1020 is a hydroxylamine-based nitroxyl (HNO) donor. CXL-1020 improves cardiac inotropy/lusitropy and Ca2+ cycling in rats with abnormal relaxation. CXL-1020 induces vasorelaxation and improves cardiac function in canine models. CXL-1020 has been used to research systolic heart failure and stable heart failure[1]. | | in vivo | CXL-1020 (100 μg/kg/min; infusion for 30 min) improves hemodynamics and cardiac function, and enhances both diastolic and systolic performance in mice[1].
CXL-1020 (3 and 10 mg/kg/min; 4-hour intravenous infusion) improves left ventricular systolic and diastolic function in dogs with advanced heart failure[2]. | Animal Model: | Adult male Sprague-Dawley rats (250-350 g; induced cardiac dysfunction by isoproterenol)[1] | | Dosage: | 100 μg/kg/min | | Administration: | For 30 min | | Result: | Improved hemodynamics and cardiac function in normal rats, and enhanced both diastolic and systolic performance in cardiac dysfunction mice. |
| Animal Model: | Dogs (coronary microembolization-induced heart failure)[2]
3 and 10 mg/kg/min | | Dosage: | 3 and 10 mg/kg/min | | Administration: | 4-hour intravenous infusion | | Result: | Decreased systolic aortic pressure (AoP) modestly; significantly increased EF and deceleration time of early mitral inflow velocity (DT) and significantly lowered left ventricular (LV) end-systolic volume (ESV), LV end-diastolic pressure (EDP) and end-diastolic wall stress (EDWS) in a dose-dependent manner. |
| | IC 50 | L-type calcium channel | | References | [1] Roof SR, et al. CXL-1020, a Novel Nitroxyl (HNO) Prodrug, Is More Effective than Milrinone in Models of Diastolic Dysfunction-A Cardiovascular Therapeutic: An Efficacy and Safety Study in the Rat. Front Physiol. 2017 Nov 10;8:894. DOI:10.3389/fphys.2017.00894
[2] Mengjun Wang, et al. Intravenous Infusion of CXL-1020, a Novel Nitroxyl (HNO) Donor, Improves Left Ventricular Systolic and Diastolic Function in Dogs with Advanced Heart Failure. CARDIOVASCULAR PHARMACOLOGY. VOLUME 15, ISSUE 6, SUPPLEMENT, S73-S74, AUGUS |
| | CXL-1020 Preparation Products And Raw materials |
|